Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC)

被引：0
|
作者：
Zarba, Martin
Ferrier, Evan
Wells, Connor
El Zarif, Talal
Basappa, Naveen S.
Ebrahimi, Hedyeh
Mckay, Rana R.
Wood, Lori
Beuselinck, Benoit
Suarez, Cristina
Takemura, Kosuke
Lalani, Aly-Khan A.
Li, Haoran
Spain, Lavinia Anne
Templeton, Arnoud J.
Powles, Thomas
Bjarnason, Georg A.
de Velasco, Guillermo
Choueiri, Toni K.
Heng, Daniel Yick Chin
机构：
[1] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[2] Tom Baker Canc Clin, Calgary, AB, Canada
[3] Barts Canc Inst, London, England
[4] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[5] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada
[6] City Hope Comprehens Canc Ctr, Duarte, CA USA
[7] Univ Calif San Diego, La Jolla, CA USA
[8] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada
[9] UZ Leuven, Leuven, Belgium
[10] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Med Oncol, Barcelona, Spain
[11] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[12] McMaster Univ, Hamilton, ON, Canada
[13] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[14] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[15] St Clara Hosp, Basel, Switzerland
[16] Queen Mary Univ London, Barts Canc Inst, London, England
[17] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[18] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[19] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4514
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
    Saliby, R. M.
    Xie, W.
    Wells, J. C.
    Saad, E.
    Eid, M.
    Semaan, K.
    Labaki, C.
    Ferrier, E.
    Zarba, M.
    Ebrahimi, H.
    Suarez Rodriguez, C.
    Ruiz, J. M.
    Powles, T. B.
    Wood, L. A.
    De Velasco Oria, G. A.
    Takemura, K.
    Braun, D. A.
    Heng, D. Y. C.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1021 - S1022
  • [32] External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database
    Yekeduz, Emre
    Karakaya, Serdar
    Erturk, Ismail
    Tural, Deniz
    Ucar, Gokhan
    Oztas, Nihan Senturk
    Arikan, Rukiye
    Hizal, Mutlu
    Kucukarda, Ahmet
    Sever, Ozlem Nuray
    Arslan, Cagatay
    Can, Orcun
    Kilickap, Saadettin
    Yazgan, Coskun
    Karadurmus, Nuri
    Sendur, Mehmet Ali
    Cicin, Irfan
    Demirci, Umut
    Ozguroglu, Mustafa
    Oksuzoglu, Berna
    Urun, Yuksel
    CLINICAL GENITOURINARY CANCER, 2023, 21 (01) : 175 - 182
  • [33] Outcomes of "real world" treatment for metastatic renal cell carcinoma (mRCC).
    Harrison, Michael Roger
    George, Daniel J.
    Walker, Mark S.
    Hudson, Lori L.
    Chen, Connie
    Korytowsky, Beata
    Stepanski, Edward J.
    Abernethy, Amy P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [34] Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
    Gan, Chun Loo
    Wells, J. Connor
    Schmidt, Andrew Lachlan
    Powles, Thomas
    Tran, Ben
    Meza, Luis A.
    Labaki, Chris
    Lee, Jae-Lyun
    Wood, Lori
    Shapiro, Julia
    Ernst, D. Scott
    Kapoor, Anil
    Canil, Christina M.
    Yuasa, Takeshi
    McKay, Rana R.
    Beuselinck, Benoit
    Donskov, Frede
    Dudani, Shaan
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.
    Heng, Daniel Yick Chin
    Wells, Connor
    Donskov, Frede
    Rini, Brian I.
    Lee, Jae-Lyun
    Bjarnason, Georg A.
    Beuselinck, Benoit
    Smoragiewicz, Martin
    Alva, Ajjai Shivaram
    Srinivas, Sandy
    Wood, Lori
    Yamamoto, Haru
    Ernst, D. Scott
    Pal, Sumanta Kumar
    Yuasa, Takeshi
    Broom, Reuben James
    Kanesvaran, Ravindran
    Bamias, Aristotelis
    Knox, Jennifer J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [36] The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT)
    Ko, Jenny J.
    Xie, Wanling
    Heng, Daniel Yick Chin
    Kroeger, Nils
    Lee, Jae-Lyun
    Rini, Brian I.
    Knox, Jennifer J.
    Bjarnason, Georg A.
    Harshman, Lauren Christine
    Pal, Sumanta Kumar
    Yuasa, Takeshi
    Smoragiewicz, Martin
    Donskov, Frede
    Bamias, Aristotelis
    Wood, Lori
    Ernst, D. Scott
    Agarwal, Neeraj
    Vaishampayan, Ulka N.
    Rha, Sun Young
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [37] Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK
    de Liano, Alfonso Gomez
    Venugopal, Balaji
    Fife, Kate
    Khasti, Luma
    Symeonides, Stefan N.
    Pettinger, Claire
    Powles, Thomas
    Rudman, Sarah Maria
    Vasudev, Naveen
    Boleti, Ekaterini
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Efficacy of VEGFR-TKI plus immune checkpoint inhibitor (ICI) in metastatic renal cell carcinoma (mRCC) patients with favorable IMDC prognosis.
    Ciccarese, Chiara
    Iacovelli, Roberto
    Bria, Emilio
    Schinzari, Giovanni
    Rossi, Ernesto
    Astore, Serena
    Cannella, Maria Antonella
    D'Angelo, Tatiana
    Cicala, Carlo Maria
    Maratta, Maria Grazia
    Tortora, Giampaolo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [39] First-line (1L) immuno-oncology (10) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Dudani, Shaan
    Graham, Jeffrey
    Wells, Connor
    Pal, Sumanta K.
    Dizman, Nazli
    Donskov, Frede
    Bjarnason, Georg A.
    Hansen, Aaron Richard
    Iafolla, Marco Adelmo James
    Vaishampayan, Ulka N.
    Porta, Camillo
    Beuselinck, Benoit
    Yan, Flora
    Wood, Lori
    Liow, Elizabeth Chien Hern
    Kollmannsberger, Christian K.
    Yuasa, Takeshi
    Zhang, Chiyuan A.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [40] Predictors of first line systemic therapy for metastatic renal cell carcinoma in IMDC favorable risk patients.
    Mizuno, Ryuichi
    Takamatsu, Kimiharu
    Tanaka, Nobuyuki
    Hayakawa, Nozomi
    Kosaka, Takeo
    Kikuchi, Eiji
    Oya, Mototsugu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345